Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday

Allogene Therapeutics (NASDAQ:ALLO) is anticipated to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $0.0020 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Trading Down 2.9%

Shares of ALLO stock traded down $0.07 during trading on Tuesday, hitting $2.20. The company’s stock had a trading volume of 1,613,257 shares, compared to its average volume of 8,483,239. The company has a market cap of $537.38 million, a PE ratio of -2.52 and a beta of 0.46. The business has a fifty day moving average of $2.41 and a 200-day moving average of $1.79. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $4.46.

Insiders Place Their Bets

In other Allogene Therapeutics news, CEO David D. Chang sold 47,763 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $2.47, for a total transaction of $117,974.61. Following the completion of the transaction, the chief executive officer directly owned 5,150,599 shares of the company’s stock, valued at approximately $12,721,979.53. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 72,183 shares of company stock worth $177,771 over the last three months. 13.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Allogene Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV grew its holdings in Allogene Therapeutics by 23.0% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company’s stock valued at $40,000 after purchasing an additional 5,514 shares during the period. CANADA LIFE ASSURANCE Co grew its holdings in Allogene Therapeutics by 27.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company’s stock valued at $50,000 after purchasing an additional 8,519 shares during the period. Zacks Investment Management grew its holdings in Allogene Therapeutics by 2.7% during the third quarter. Zacks Investment Management now owns 526,132 shares of the company’s stock valued at $652,000 after purchasing an additional 13,831 shares during the period. Intech Investment Management LLC grew its holdings in Allogene Therapeutics by 20.5% during the fourth quarter. Intech Investment Management LLC now owns 86,637 shares of the company’s stock valued at $119,000 after purchasing an additional 14,742 shares during the period. Finally, Virtu Financial LLC grew its holdings in Allogene Therapeutics by 55.9% during the fourth quarter. Virtu Financial LLC now owns 42,351 shares of the company’s stock valued at $58,000 after purchasing an additional 15,178 shares during the period. 83.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on ALLO. Citigroup reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Tuesday, April 14th. Sanford C. Bernstein upped their target price on Allogene Therapeutics from $1.60 to $3.85 and gave the company a “market perform” rating in a report on Tuesday, April 14th. Robert W. Baird upped their target price on Allogene Therapeutics from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Tuesday, April 14th. Piper Sandler upped their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, March 13th. Finally, UBS Group began coverage on Allogene Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $8.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $8.44.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.